The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
Open accessAbstract
Objective: To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA). Methods: In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double‐blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse‐free survival rate). Results: Forty‐nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; of these, 41 reached the week 12 randomization and underwent a blinded randomization to receive abatacept or placebo. Prednisone was tapered using a standardized schedule, reaching a daily dosage of 20 mg at week 12 with discontinuation in all patients at week 28. The relapse‐free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (P = 0.049). A longer median duration of remission was seen in those receiving abatacept compared to those receiving placebo (median duration 9.9 months versus 3.9 months; P = 0.023). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms. Conclusion: In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Hunder, G. G., Bloch, D. A., Michel, B. A., Stevens, M. B., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330810 · Cited by 2,539
The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis
Arend, W. P., Michel, B. A., Bloch, D. A., Hunder, G. G., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., Lightfoot, R. W., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330811 · Cited by 2,267
Polymyalgia Rheumatica and Giant-Cell Arteritis
Salvarani, C., Cantini, F., Boiardi, L., & Hunder, G. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011913 · Cited by 1,352
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
Self-citationMedium- and Large-Vessel Vasculitis
Weyand, C. M., & Goronzy, J. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022694 · Cited by 788
Mahr, A. D., Jover, J. A., Spiera, R. F., Hernández‐García, C., Fernández‐Gutiérrez, B., LaValley, M. P., & Merkel, P. A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22754 · Cited by 622
Self-citationTakayasu arteritis. A study of 32 North American patients.
Hall, S., Barr, W. G., Lie, J. T., Stanson, A. W., Kazmier, F. J., & Hunder, G. G. (1985) · PubMed · Cited by 620
Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes
Proven, A., Gabriel, S. E., Orces, C., O'Fallon, W. M., & Hunder, G. G. (2003) · Arthritis Care & Research · doi:10.1002/art.11388 · Cited by 612
Hoffman, G. S., Cid, M. C., Hellmann, D. B., Guillevin, L., Stone, J. H., Schousboe, J., Cohen, P., Calabrese, L. H., Dickler, H., Merkel, P. A., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10262 · Cited by 579
Self-citation
Cited by
Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215672 · Cited by 1,200
Maz, M., Chung, S. A., Abril, A., Langford, C. A., Gorelik, M., Guyatt, G., Archer, A. M., Conn, D. L., Full, K. A., Grayson, P. C., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41774 · Cited by 654
Self-citationWriting group, Slart, R. H. J. A., Reviewer group, Cardiovascular, M. O. E., Inflammation, M. O. E. I. &., Members of Committees, S. C., Members of Council, P. I. G., Members of, A. S. N. C., & EANM Committee Coordinator (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3973-8 · Cited by 503
González-Gay, M. A., Matteson, E. L., & Castañeda, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31825-1 · Cited by 262
Metadata
- Authors
- Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., Sreih, A. G., Spiera, R., McAlear, C. A., Warrington, K. J., Pagnoux, C., McKinnon, K., Forbess, L. J., Hoffman, G. S., Borchin, R., Krischer, J. P., Merkel, P. A., & for the Vasculitis Clinical Research Consortium
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2017-03-03
- Volume
- 69
- Issue
- 4
- Pages
- 837-845
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2581891606
- Cited by
- 394
- References
- 38
- FWCI
- 35.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis. https://app.cochat.ai/papers/10.1002/art.40044
- The paper
- Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., Sreih, A. G., Spiera, R., McAlear, C. A., Warrington, K. J., Pagnoux, C., McKinnon, K., Forbess, L. J., Hoffman, G. S., Borchin, R., . . . for the Vasculitis Clinical Research Consortium. (2017). A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.40044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.